News Search Results
Jun 12, 2026, 09:00 ET Promising First-in-Patient Results for ACOU085 (INN: Bimokalner) in Cisplatin-Induced Ototoxicity
TÜBINGEN, Germany, June 12, 2026 /PRNewswire/ -- Acousia Therapeutics GmbH, a clinical-stage biotechnology company pioneering treatments for acute and chronic inner ear hearing loss, today announced positive top-line efficacy results from its completed
More news about: Acousia Therapeutics GmbH
Jun 12, 2026, 08:59 ET From Cancer Drugs to Kilowatts: A NASDAQ Company's Bet on the AI Power Crunch
[email protected](604) 265-2873SOURCES:LIXTE Biotechnology Holdings, Inc. — "LIXTE Biotechnology to Acquire NOMAD Transportable Power Systems…" (company press release, June 2026; acquisition, NOMAD platform, permitting advantages,
More news about: USA News Group
Jun 12, 2026, 04:00 ET Promising First-in-Patient Results for ACOU085 (INN: Bimokalner) in Cisplatin-Induced Ototoxicity
TÜBINGEN, Germany, June 12, 2026 /PRNewswire/ -- Acousia Therapeutics GmbH, a clinical-stage biotechnology company pioneering treatments for acute and chronic inner ear hearing loss, today announced positive top-line efficacy results from its completed
More news about: Acousia Therapeutics GmbH
Jun 12, 2026, 03:00 ET Beyond the Double Helix: Phinomics Joins "All Access hosted by Andy Garcia" to Explore Hidden Frontiers in Genetics
The short-form documentary production "All Access hosted by Andy Garcia" is set to film an upcoming educational segment highlighting Phinomics, a biotechnology group mapping this hidden cellular architecture to fundamentally shift how we understand human health.
More news about: All Access
Jun 11, 2026, 21:19 ET Harbour BioMed Appoints Dr. Dhavalkumar Patel as Scientific Advisor
spanning over two decades in industry and academia. He is currently Executive Vice President and Chief Scientific Officer of Sana Biotechnology.Prior to joining Sana Biotechnology in 2024, Dr. Patel served as Executive Vice President and Chief Scientific Officer of UCB, where he and his teams contributed
More news about: Harbour BioMed
Jun 11, 2026, 21:15 ET Peer-reviewed Publication Shows that Lateral Pharma's SCP Drugs for Neuropathic Pain Act Via the Novel Target LanCL1
Evotec and Lateral Pharma, and is now available online through PAIN.About Lateral PharmaLateral Pharma is an Australian biotechnology company developing a new class of therapeutics based on the activation of LanCL pathways involved in cellular protection, repair and recovery. The
More news about: LATERAL PHARMA PTY LTD
Jun 11, 2026, 17:15 ET ChronicleBio Is Coming for Chronic Disease: Pioneering Immunologist Joins Elite Scientific Team to Translate Biological Signal into Targeted Therapeutics
establishing, that are creating a curative model for a chronically broken system.ABOUT CHRONICLEBIOChronicleBio is a data-driven biotechnology company applying multi-omic endotyping and artificial intelligence to decode the molecular architecture of complex chronic conditions. The company's
More news about: ChronicleBio
Jun 11, 2026, 14:57 ET Jennifer Biro Named a 2026 Philadelphia Titan 100 Honoree for Second Consecutive Year
business development initiatives. Her leadership has played a key role in expanding CleanSpace's presence across the life sciences, pharmaceutical, biotechnology, healthcare, semiconductor, battery manufacturing, and advanced technology sectors. Through a customer-focused approach and commitment to long-term
More news about: CleanSpace Modular, LLC
Jun 11, 2026, 11:56 ET Rubin Rudman Adds Julia Royce in Corporate, Business and Tax Practice
Rubin Rudman serves national and international companies, including large public companies and closely held businesses; real estate developers; biotechnology, pharmaceutical and medical device makers; hospitality companies; regulated industries, public entities and municipalities; insurance companies
More news about: Rubin Rudman
Jun 11, 2026, 11:43 ET Louisiana leads with first-of-its-kind population health initiative providing personalized immune insights
Phenomune, a biotechnology company focused on health and wellness, and the
More news about: Phenomune
Jun 11, 2026, 10:07 ET Lifespan Portfolio Company Rejuvenate Bio Closes $6 Million Financing and R&D Collaboration with Merck Animal Health
interventions.About Lifespan Vision VenturesLifespan Vision Ventures is a global venture capital firm investing in early-stage biotechnology companies developing breakthrough technologies to prevent and treat age-related diseases. The firm partners with visionary founders advancing science-driven
More news about: LifeSpan Vision Ventures
Jun 11, 2026, 10:01 ET Chromatography Accessories & Consumables Market worth $12.14 billion by 2031 | MarketsandMarkets™
chromatography segment is expected to register the highest CAGR of 7.7% during the forecast period.By end user, the pharmaceutical & biotechnology industries held a 36.0% share of the chromatography accessories and consumables market in 2025.Asia Pacific is likely to record the higest
More news about: MarketsandMarkets
Jun 11, 2026, 10:00 ET Pomerantz Law Firm Announces the Filing of a Class Action Against Regencell Bioscience Holdings Limited and Certain Officers - RGC
$14 billion. As The Wall Street Journal observed in January 2026, "[f]or context, only 20 of the 261 companies in the Nasdaq Biotechnology Index had a greater market value; the index doesn't include Regencell." At all relevant times, Defendants downplayed the likelihood and severity
More news about: Pomerantz LLP
Jun 11, 2026, 09:59 ET Lifespan Portfolio Company Rejuvenate Bio Closes $6 Million Financing and R&D Collaboration with Merck Animal Health
interventions.About Lifespan Vision VenturesLifespan Vision Ventures is a global venture capital firm investing in early-stage biotechnology companies developing breakthrough technologies to prevent and treat age-related diseases. The firm partners with visionary founders advancing science-driven
More news about: LifeSpan Vision Ventures
Jun 11, 2026, 09:35 ET Lost Money on Regencell Bioscience Holdings Limited (RGC)? Join Class Action Suit Seeking Recovery - Contact SueWallSt
$1 million annually on research and development. The Wall Street Journal noted in January 2026 that only 20 of the 261 companies in the Nasdaq Biotechnology Index carried a greater market value. The lawsuit contends that this extraordinary valuation disconnect was fueled by trading activity unrelated
More news about: SueWallSt.com
Jun 11, 2026, 09:30 ET SCbio Spotlights South Carolina's Leading Life Sciences Industry at BIO International in San Diego
BIO 2026, the annual international convention hosted by Biotechnology Innovation Organization June 22-25 in San Diego.
More news about: SCbio
Jun 11, 2026, 09:10 ET Aspen Neuroscience Appoints Jeff Boerneke as General Counsel and Secretary
DIEGO, June 11, 2026 /PRNewswire/ -- Aspen Neuroscience, Inc., a clinical-stage regenerative medicine biotechnology company developing personalized, autologous cell therapies, today announced the appointment of Jeff Boerneke as General Counsel and Secretary.
More news about: Aspen Neuroscience, Inc.
Jun 11, 2026, 09:05 ET Anixa Biosciences Announces Presentations of Two Clinical-Stage Immunotherapy Programs at New York Academy of Sciences' Frontiers in Cancer Immunotherapy Symposium
Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that two of its clinical-stage immunotherapy programs will be presented
More news about: Anixa Biosciences, Inc.
Jun 11, 2026, 09:00 ET NeuroSense Granted South Korean Patent Covering PrimeC Composition for ALS
NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) ("NeuroSense" or the "Company"), a late-clinical stage biotechnology company developing novel treatments for severe neurodegenerative diseases, today announced that the Korean Intellectual Property Office (KIPO) has
More news about: NeuroSense
Jun 11, 2026, 08:28 ET Immorta Bio Publishes Over 70% Increased Longevity in Aging Animals by its Patented Therapeutic Combination
MIAMI and SAN DIEGO, June 11, 2026 /PRNewswire/ -- Immorta Bio, a scientific longevity biotechnology company focused on Treating Diseases of Aging and Treating Aging as Disease™, today announced publication of a landmark peer-reviewed study demonstrating
More news about: Immorta Bio Inc.
Jun 11, 2026, 08:04 ET Rocket One Announces Former NASA Astronaut and International Space Station Commander Shane Kimbrough to Join Rocket One Space Advisory Board
defense and space systems. The Company is also positioned to pursue opportunities in nano-launch systems and nanosatellite deployment. The Company's biotechnology pipeline, including, but not limited to, HT-001, HT-KIT, HT-ALZ, and its GDNF-based metabolic program, will continue to be advanced under a wholly
More news about: Rocket One Inc.
Jun 11, 2026, 07:05 ET Viking Therapeutics Announces Appointment of Hubert C. Chen, M.D., as Chief Medical Officer
commercialization," said Brian Lian, Ph.D., president and chief executive officer of Viking Therapeutics. "He is an accomplished physician, scientist, and biotechnology executive with an impressive combination of scientific, clinical, regulatory, and operational expertise, along with extensive knowledge of obesity,
More news about: Viking Therapeutics, Inc.
Jun 11, 2026, 05:00 ET Exyte secures three major AI-driven data center projects near Frankfurt - supporting 400 jobs in Germany
developed over more than a century, the company serves clients in the sophisticated markets of semiconductors, battery cells, pharmaceuticals, biotechnology, and data centers. Exyte offers a full range of services from consulting to managing the implementation of built complete solutions with the highest
More news about: Exyte
Jun 11, 2026, 05:00 ET Exyte secures three major AI-driven data center projects near Frankfurt - supporting 400 jobs in Germany
developed over more than a century, the company serves clients in the sophisticated markets of semiconductors, battery cells, pharmaceuticals, biotechnology, and data centers. Exyte offers a full range of services from consulting to managing the implementation of built complete solutions with the highest
More news about: Exyte
Jun 11, 2026, 04:22 ET Peer-reviewed publication shows that Lateral pharma's SCP drugs for neuropathic pain act via the novel target LanCL1
composition-of-matter patent covering LAT9997 for the treatment of neuropathic pain.About Lateral PharmaLateral Pharma is an Australian biotechnology company developing a new class of therapeutics based on the activation of LanCL pathways involved in cellular protection, repair and recovery. The
More news about: Lateral Pharma